Insight Molecular Diagnostics Inc (IMDX)
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
$4.13+0.24%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
QuarterlyIQ Insights · IMDX
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
of this Current Report on Form 8-K, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. Such information shall not be deemed incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless…
Cautionary Note Regarding Forward-Looking Statements Certain statements in this Current Report on Form 8-K may be considered “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements other than statements of historical fact contained in this Current Report. Such forward-looking statements are subject to risks, uncertainties, and other factors which cou…
The excerpt is incomplete and does not provide sufficient information to determine the nature of the event.
of this Current Report on Form 8-K, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. Such information shall not be deemed incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless…
announcing that it had entered into a Specimen Collection Agreement with Quest Diagnostics Incorporated (“Quest Diagnostics”). This information was inadvertently filed under
of this Current Report on Form 8-K, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. Such information shall not be deemed incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless…
Entry into a Material Definitive Agreement. On February 20, 2026, Insight Molecular Diagnostics Inc. (the “Company”) entered into a Specimen Collection Agreement (the “Agreement”) with Quest Diagnostics Incorporated (“Quest Diagnostics”). Pursuant to the Agreement, Quest Diagnostics will provide certain specimen collection-related services related to specimens upon which Provider will perform a GraftAssureCore™ test, a blood test designed to measure donor-derived cell free DNA (dd-cfDNA) usin…
Entry into a Material Definitive Agreement. On February 10, 2026, Insight Molecular Diagnostics Inc. (the “ Company ”) entered into securities purchase agreements (the “ Purchase Agreements ”) with certain institutional investors, pursuant to which the Company agreed to issue and sell (i) 3,482,498 shares (the “ Shares ”) of the Company’s common stock, no par value per share (the “ Common Stock ”), and (ii) Pre-Funded Warrants (the “ Pre-Funded Warrants ”) to purchase up to 1,043,478 shares o…
of this Current Report on Form 8-K, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. Such information shall not be deemed incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless…
The filing details compensatory arrangements and an employment agreement amendment, not a management change.
The filing details salary increases for the CEO and CFO.
of this Current Report on Form 8-K, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. Such information shall not be deemed incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless…
of this Current Report on Form 8-K, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. Such information shall not be deemed incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless…
Changes in Registrant’s Certifying Accountant. Based on information provided by Marcum LLP (“Marcum”), the independent registered public accounting firm of Oncocyte Corporation, a California corporation (the “Company”), CBIZ CPAs P.C. (“CBIZ CPAs”) acquired the attest business of Marcum, effective November 1, 2024. Marcum continued to serve as the Company’s independent registered public accounting firm through April 11, 2025. On April 11, 2025, the Company terminated its relationship with Mar…
of this Current Report on Form 8-K, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. Such information shall not be deemed incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless…
Vice President Accounting, Controller, Treasurer and Principal Accounting Officer — James Liu: Promotion of James Liu to Vice President Accounting, Controller, Treasurer and Principal Accounting Officer.
shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act or into any filing or other document pursuant to the Exchange Act, except as otherwise expressly stated in any such filing. Cautionary Note Regarding Forward-looking Statements This Current Report on Form 8-K includes forward-looking statements including without limitation statements regarding the transactions contemplated by the Purchase Agreements, the expected closing of…
Unregistered Sales of Equity Securities. The information contained in
Termination of a Material Definitive Agreement. On February 6, 2025, the Company provided notice of its intention to terminate that certain Sales Agreement dated as of August 9, 2024 (the “Sales Agreement”), by and between the Company and Needham & Company, LLC (“Needham”), pursuant to which, the Company could offer and sell from time to time up to an aggregate of $7,500,000 of Common Stock through Needham in transactions deemed to be “at-the-market” offerings as defined in Rule 415(a)(4) of…
Entry Into a Material Definitive Agreement. Private Placement Transaction On February 7, 2025, Oncocyte Corporation (the “Company”) entered into a securities purchase agreement (the “PIPE Purchase Agreement”) with certain accredited investors (collectively, the “Purchasers”) for the issuance and sale in a private placement (the “Private Placement”) of an aggregate of 7,536,708 shares (the “Common Shares”) of common stock of the Company, no par value per share (the “Common Stock”), and pre-fun…
Entry into a Material Definitive Agreement. Effective as of January 2, 2025, Oncocyte Corporation (the “Company”) entered into an Amendment to and Waiver of Right to Extend Original Lease (the “Amendment”), dated as of December 26, 2024, with Induce Biologics USA, Inc. (“Induce”) and Cushing Ventures, LLC (“Cushing”), which amended that certain Office Lease Agreement, dated December 23, 2019 (the “Original Lease”), by and between the Company, as tenant, and Cushing, as landlord. Pursuant to t…
of this Current Report on Form 8-K, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. Such information shall not be deemed incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless…
The filing appears to be about compensatory arrangements rather than a management change.
Other Events. On October 2, 2024, the Company issued a press release announcing the Private Placement. A copy of the press release is attached as Exhibit 99.3 to this Current Report on Form 8-K and is hereby incorporated by reference herein. Cautionary Note Regarding Forward-looking Statements This Current Report on Form 8-K includes forward-looking statements including without limitation statements regarding the transactions contemplated by the Purchase Agreement, the expected closing of the…
Unregistered Sales of Equity Securities. The information contained in
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.